Factor V Leiden is a risk factor for myocardial infarction in young Turkish men

Acta Cardiologica

Volumn 59, Issue 6, 2004, Pages 594-597

  Hobikoglu, Gultekin F ^a   Akyuz, Umit ^b   Akyuz, Filiz ^b   Ozer, Orhan ^a   Güney, Dilvin ^c   Narin, Ahmet ^a   Unaltuna, Nihan ^c  

^a Siyami Ersek Thorac Cardiovasc S ^*  (Turkey)

^b HAYDARPASA NUMUNE HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Coronary thrombosis; Factor V Leiden; Myocardial infarction

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DNA;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; GENDER; HEALTH STATUS; HEART INFARCTION; HUMAN; MALE; MUTATION; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEX DIFFERENCE; TURKEY (REPUBLIC);

EID: 10244222783     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.59.6.2005240     Document Type: Article

References (30)

1. Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, Ronde H de, Van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-8.
2. Greengard JS, Sun X, Xu X, Fernandez GA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1362-7.
3. Zöller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-40.
4. Voorberg J, Roelse J, Koopman B, Buller H, Berends F, Cate JW, Mertens K, van Mourik JA. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V Lancet 1994; 343: 1535-9.
5. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-9.
6. Lindblad B, Svensson PJ, Dahlback B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C. Lancet 1994; 343: 917-21.
7. Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlback B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344: 952-7.
8. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995; 345: 526-30.
9. Kontula K, Ylikorkala A, Miettinen H. Vuorio A, Kauppinen-Makelin R, Hamalainen L, Palomaki H, Kaste M. Arg506Gln Factor V mutation (Factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-62.
10. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-6.
11. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321-5.
12. Van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V Nat Med 1995; 1: 185-9.
13. Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg506→Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996; 75: 701-6.
14. World Health Organization. Ischemic heart disease registers: report of the Fifth Work Group, including a second revision of the operating protocol, Copenhagen, Denmark, April 26-29, 1971. Copenhagen, Denmark: World Health Organization, Regional Office for Europe, 1971.
15. Millar SA, Dijkes DD, Polesky HF. A simple salting out procedure for extracting DNA from nucleated cells. Nucleic Acids Res 1988; 16: 1215-9.
16. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA. Angioscopic evaluation of coronary artery thrombi in acute coranary syndromes. N Engl J Med 1992; 326: 287-91.
17. DiSciascio G, Cowley MJ, Goudreau E, Vetrovec GW, Johnson DE. Histopathologic correlates of unstable ischemice syndromes in patients undergoing directional coronary atherectomy: in vivo evidence of thrombosis, ulceration and inflammation. Am Heart J 1994; 128: 419-26.
18. Koster T, Rosendaal FR, Ronde H de, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-8.
19. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
20. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-10.
21. Rosendaal FR, Bertina RM, Reitsma PH. Evaluation of activated protein C resistance in stored plasma. Lancet 1994; 343: 1289-95.
22. Takamiya O, Ishida F, Kodaira H. APC resistance and Mn1 I genotype (Gln 506) of coagulation factor V are rare in the Japanese population. Thromb Haemost 1995; 74: 996-9.
23. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
24. Gurgey A, Mesci L. Prevalence of factor V Leiden (1691 G A mutation in Turkey. Turk J Pediatr 1997; 39(3): 313-5.
25. Van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ. Prevalence of factor V Leiden and prothrombin variant G20210A in patients aged < 50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 2000; 36(3): 717-22.
26. Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C, Isaaz K, Blanc JJ. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000; 83(6): 822-5.
27. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995; 345: 526.
28. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth Jr WT, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated Protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89(8): 2817-21.
29. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-6.
30. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321.